Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CADL NASDAQ:CDTX NASDAQ:CRGX NYSE:RCOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCADLCandel Therapeutics$6.74-2.6%$5.48$3.79▼$14.60$337.69M-0.911.52 million shs711,469 shsCDTXCidara Therapeutics$59.96+6.8%$34.15$10.14▼$61.60$1.21B1.14213,412 shs1.11 million shsCRGXCARGO Therapeutics$4.57-0.4%$4.33$3.00▼$25.45$210.72M0.28735,885 shs1.74 million shsRCORRenovacor$3.20$3.07$1.34▼$9.74$55.26M-0.2830,033 shsN/A7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCADLCandel Therapeutics-2.60%+16.01%+36.99%+47.48%+2.59%CDTXCidara Therapeutics+6.79%+18.66%+181.37%+208.44%+360.88%CRGXCARGO Therapeutics-0.44%-0.44%+5.06%-1.51%-74.06%RCORRenovacor0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCADLCandel Therapeutics2.5795 of 5 stars3.61.00.00.03.41.70.6CDTXCidara Therapeutics3.6546 of 5 stars2.62.00.04.63.71.70.0CRGXCARGO Therapeutics2.3536 of 5 stars2.90.00.00.02.71.71.3RCORRenovacorN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCADLCandel Therapeutics 3.20Buy$22.00226.41% UpsideCDTXCidara Therapeutics 3.11Buy$57.29-4.46% DownsideCRGXCARGO Therapeutics 1.86Reduce$15.40236.98% UpsideRCORRenovacor 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RCOR, CADL, CRGX, and CDTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025CDTXCidara TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$69.007/9/2025CADLCandel TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/8/2025CRGXCARGO TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$3.70 ➝ $5.006/30/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$23.006/30/2025CDTXCidara TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$59.006/24/2025CDTXCidara TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/24/2025CDTXCidara TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$35.00 ➝ $75.006/24/2025CDTXCidara TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$50.00 ➝ $68.006/23/2025CDTXCidara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$41.00 ➝ $53.006/23/2025CDTXCidara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$36.00 ➝ $54.006/23/2025CDTXCidara TherapeuticsWBB SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy$45.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCADLCandel Therapeutics$120K2,813.95N/AN/A$1.41 per share4.78CDTXCidara Therapeutics$1.27M951.81N/AN/A$14.92 per share4.02CRGXCARGO TherapeuticsN/AN/AN/AN/A$7.83 per shareN/ARCORRenovacorN/AN/AN/AN/A$2.47 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCADLCandel Therapeutics-$55.18M-$1.34N/AN/AN/AN/A-136.74%-63.13%8/12/2025 (Estimated)CDTXCidara Therapeutics-$169.83M-$29.47N/AN/AN/AN/A-73.04%-54.28%8/12/2025 (Estimated)CRGXCARGO Therapeutics-$167.50M-$4.62N/AN/AN/AN/A-45.93%-39.58%8/11/2025 (Estimated)RCORRenovacor-$14.10M-$0.73N/AN/AN/AN/A-62.88%-48.90%N/ALatest RCOR, CADL, CRGX, and CDTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025CADLCandel Therapeutics-$0.17N/AN/AN/AN/AN/A8/12/2025Q2 2025CDTXCidara Therapeutics-$1.87N/AN/AN/AN/AN/A8/11/2025Q2 2025CRGXCARGO Therapeutics-$0.42N/AN/AN/AN/AN/A5/13/2025Q1 2025CADLCandel Therapeutics-$0.24$0.13+$0.37$0.13N/AN/A5/8/2025Q1 2025CDTXCidara Therapeutics-$5.45-$1.66+$3.79-$1.66N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCADLCandel TherapeuticsN/AN/AN/AN/AN/ACDTXCidara TherapeuticsN/AN/AN/AN/AN/ACRGXCARGO TherapeuticsN/AN/AN/AN/AN/ARCORRenovacorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCADLCandel Therapeutics0.014.644.64CDTXCidara TherapeuticsN/A3.873.87CRGXCARGO TherapeuticsN/A6.306.30RCORRenovacorN/A6.606.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCADLCandel Therapeutics13.93%CDTXCidara Therapeutics35.82%CRGXCARGO Therapeutics93.16%RCORRenovacor45.84%Insider OwnershipCompanyInsider OwnershipCADLCandel Therapeutics16.60%CDTXCidara Therapeutics3.89%CRGXCARGO Therapeutics2.92%RCORRenovacor14.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCADLCandel Therapeutics6050.10 million41.79 millionOptionableCDTXCidara Therapeutics9020.16 million19.38 millionNo DataCRGXCARGO Therapeutics11646.11 million44.76 millionN/ARCORRenovacor1917.27 million14.78 millionNot OptionableRCOR, CADL, CRGX, and CDTX HeadlinesRecent News About These CompaniesRenovacor, Inc. Common Stock (RCOR)June 12, 2025 | nasdaq.comBest budget record players 2024: affordable turntables tried and testedNovember 6, 2024 | whathifi.comWThe Lititz Record-ExpressOctober 25, 2024 | lancasteronline.comLWNBA Delivers Record-Setting 2024 SeasonOctober 13, 2024 | wnba.comWRBC Core Bond Pool ETF (RCOR)July 27, 2024 | investing.comRecord Store Day 2024: How to Flatten Warped Vinyl Records at HomeApril 22, 2024 | cnet.comThe best record players 2024: Top turntables for any budgetApril 20, 2024 | tomsguide.comTBest turntables 2024: Bluetooth record players for Record Store DayApril 20, 2024 | stuff.tvSNews of RecordMarch 30, 2024 | newsandsentinel.comNNHL opening night delivers record viewership on ESPNNovember 6, 2023 | nhl.comNState Pension payments worth over £2,000 each month for older people living in these European countriesOctober 30, 2023 | dailyrecord.co.ukDThe best early Black Friday turntable deals 2023October 28, 2023 | whathifi.comWAnas Sarwar 'unhappy' with Keir Starmer over Labour leader's response to Gaza crisisOctober 27, 2023 | dailyrecord.co.ukDNYC shoplifting hit record highs last year: ‘We can’t stop them’October 24, 2023 | nypost.comNTranscriptional control of the inflammatory responseOctober 18, 2023 | nature.comNRockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of DirectorsOctober 17, 2023 | finance.yahoo.comFolwell criticizes fellow Republicans on public records rollbackOctober 14, 2023 | wral.comWBest Bluetooth turntables 2023: wireless record players for streaming vinylOctober 11, 2023 | whathifi.comWHere’s why you shouldn’t record meltdowns on an airplane: FAA insiderOctober 3, 2023 | nypost.comNRecord-breaking heat wave peaking in Eastern U.S. with highs near 100September 28, 2023 | washingtonpost.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRCOR, CADL, CRGX, and CDTX Company DescriptionsCandel Therapeutics NASDAQ:CADL$6.74 -0.18 (-2.60%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$6.78 +0.04 (+0.52%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Cidara Therapeutics NASDAQ:CDTX$59.96 +3.81 (+6.79%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$60.30 +0.34 (+0.57%) As of 07/18/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.CARGO Therapeutics NASDAQ:CRGX$4.57 -0.02 (-0.44%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$4.57 0.00 (0.00%) As of 07/18/2025 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.Renovacor NYSE:RCORRenovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.